Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Peritoneal Neoplasms 3Colorectal Neoplasms 3Appendiceal Neoplasms 3Anus Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Liver Neoplasms 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Urothelial Carcinoma Ureter 1Unspecified Adult Solid Tumor, Protocol Specific 1Solid Neoplasm 1Peritoneal Diseases 1Pancreatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Necrosis 1Lung Metastases 1Leukemia, Myeloid, Acute 1Leukemia 1Gastrointestinal Neoplasms 1Dermatitis 1

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solid Neoplasm × Mitomycin × Clear all
NCT01017640 2016-07-11

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡